Compare SBET & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBET | AMPH |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 971.8M |
| IPO Year | 2025 | 2005 |
| Metric | SBET | AMPH |
|---|---|---|
| Price | $5.39 | $18.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $18.71 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 7.7M | 604.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $28,055,000.00 | ★ $719,887,000.00 |
| Revenue This Year | $105.19 | $6.90 |
| Revenue Next Year | $13.53 | $4.64 |
| P/E Ratio | ★ N/A | $134.36 |
| Revenue Growth | ★ 666.04 | N/A |
| 52 Week Low | $5.06 | $16.65 |
| 52 Week High | $40.46 | $31.26 |
| Indicator | SBET | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 41.27 |
| Support Level | $5.06 | $17.73 |
| Resistance Level | $8.20 | $19.81 |
| Average True Range (ATR) | 0.34 | 0.75 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 40.95 | 20.23 |
SharpLink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.